Pan-SHIP1/2 inhibitors would first be employed to ablate the cancers more effectively and then SHIP1-selective inhibition after a period of recovery so that tumor-reactive cytotoxic T and NK cells can be activated and increased by SHIP1 selective inhibition to eliminate the residual cancer burden. The gene discussed is INPP5D; the disease is cancer.